With one-year EPS and revenue growth estimates of 27.44% and 19.19%, respectively, Insulet Corporation (NASDAQ:PODD) earns a place on our list of the best growth stocks to buy and hold in 2026.
Cherries/Shutterstock.com
Insulet Corporation (NASDAQ:PODD) is heading into late April 2026 with strong analyst backing. As of April 23, the majority of analysts covering the stock have a Buy rating on it, and the consensus price target of $360 points to 87% upside potential.
On April 15, 2026, Truist analyst Richard Newitter lowered the firm’s price target on Insulet Corporation (NASDAQ:PODD) to $315 from $360, a measured revision that did little to shake his overall conviction.
Newitter kept the firm’s Buy rating firmly in place, noting that first-quarter results are expected to come in line or better, even as investor sentiment around volumes stays on the cautious side. He noted that Insulet Corporation (NASDAQ:PODD) currently trades at a slight discount to its peer group of high-growth profitable companies but argued it should trade at least in line with peers, if not at a premium, given its stronger revenue and profit growth profile.
That constructive view builds on Insulet’s fourth quarter results.
Revenue came in at $783.8 million, up 31.2% (29.0% in constant currency), exceeding the company’s guidance. Omnipod delivered growth in the quarter, with total revenue reaching $781.8 million, up 33.5% year-over-year. In the U.S., revenue reached $567.8 million, up 28.0%, while international revenue grew at an even stronger rate, rising 50.7% to $214 million.
For the full year, revenue grew 30.7% to $2.7 billion, and adjusted net income came in at $354.4 million, or $4.97 per diluted share.
Looking ahead to 2026, Insulet Corporation (NASDAQ:PODD) is guiding for first-quarter total revenue growth of 25% to 27%, with full-year growth of 20% to 22%. Omnipod is targeted to grow a bit faster, with projected first-quarter growth of 28% to 30% and full-year growth of 21% to 23%. Rounding out the guidance, the company is projecting around 100 basis points of margin expansion, and adjusted EPS growth is expected to exceed 25%.
Insulet Corporation (NASDAQ:PODD) is a medical device company that develops, markets, and manufactures an insulin infusion system for people with insulin-dependent diabetes. The company specializes in diabetes supplies, along with other diabetes related products and supplies, including pump supplies, traditional insulin pumps, blood glucose testing supplies, and pharmaceuticals.
While we acknowledge the risk and potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PODD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center